
iRhythm Technologies (IRTC) Stock Forecast & Price Target
iRhythm Technologies (IRTC) Analyst Ratings
Bulls say
iRhythm Technologies has provided an optimistic outlook for 2025, with revenue guidance raised to $735M-$740M, reflecting a year-over-year growth rate of 24.6% at the midpoint, above previous estimates. The company reported an adjusted gross margin of 71.1%, marking a 230 basis point increase year-over-year and surpassing consensus expectations, which bolsters its financial health. Additionally, iRhythm continues to expand its presence internationally, particularly in Japan and the UK private market, indicating sustained growth potential driven by its core business and innovative product offerings.
Bears say
The excerpts indicate a negative outlook for iRhythm Technologies due to a forecasted slowing growth rate, projected at the low-teens, alongside concerns regarding profitability. Significant risks include regulatory scrutiny from the Department of Justice and the FDA, which could adversely affect operations and financial results, as well as heightened competition that could diminish commercial opportunities. Additionally, the company's reliance on physician adoption of its Zio service and a history of net losses further contribute to the challenges it faces in achieving sustainable profitability amidst a competitive market landscape.
This aggregate rating is based on analysts' research of iRhythm Technologies and is not a guaranteed prediction by Public.com or investment advice.
iRhythm Technologies (IRTC) Analyst Forecast & Price Prediction
Start investing in iRhythm Technologies (IRTC)
Order type
Buy in
Order amount
Est. shares
0 shares